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ABSTRACT 
Alternative splicing is a key process required for the regulation of gene expression in normal 
development and physiology. It is regulated by splice factors whose activities are in turn 
regulated by splice factor kinases and phosphatases. The CDC-like protein kinases are a 
widespread family of splice factor kinases involved in normal physiology and in several 
diseases including cancer. In humans they include the CLK1, CLK2, CLK3 and CLK4 genes. The 
expression of CLK1 is regulated through alternative splicing producing both full-length 
catalytically active and truncated catalytically inactive isoforms, CLKT1 (arising from exon 4 
skipping) and CLKT2 (arising from intron 4 retention). We examined CLK1 alternative splicing 
in a range of cancer cell lines, and report widespread and highly variable rates of exon 4 
skipping and intron 4 retention. We also examined the effect of severe environmental stress 
including heat shock, osmotic shock, and exposure to the alkaloid drug harmine on CLK1 
alternative splicing in DU145 prostate cancer cells. All treatments rapidly eliminated exon 4 
skipping and intron 4 retention, shifting the balance towards full-length CLK1 expression. We 
also found that the inhibition of CLK1 with the benzothiazole TG003 also eliminated exon 4 
skipping and intron 4 retention suggesting an autoregulatory mechanism. CLK1 inhibition with 
TG003 also resulted in modified alternative splicing of five cancer-associated genes. 
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1. Introduction 
The CLK (CDC-2 like) protein kinases phosphorylate splice factors and contribute significantly 
to the regulation of alternative splicing. The CLK1 gene was first identified in 1991 through a 
homology probing approach (Johnson and Smith, 1991). The full-length protein it encodes is 
484 amino-acids long, of which the first 130 constitute a regulatory region required for the 
interaction of CLK1 with SR proteins (splice factors with a serine/arginine-rich domain). The 
remaining amino-acids form the catalytic domain containing the conserved signature 
EHLAMMERILG (Nayler et al., 1997; Menegay et al., 2000). There are four members of the CLK 
gene family in humans (CLK1-4); of these, CLK1 and CLK4 are most closely related. CLK1, CLK2 
and CLK4 are ubiquitously expressed (Nayler et al., 1997), whereas CLK3 expression is most 
prominent in spermatozoa (Menegay et al., 1999). The developmental and physiological 
function of the four members of the CLK family is beginning to emerge. CLK2 is involved in the 
control of diet-induced thermogenesis in brown adipose tissue (Hatting et al., 2017) and is a 
suppressor of hepatic gluconeogenesis (Rodgers et al., 2010). CLK1 is required for cell cycle 
progression (Dominguez et al., 2016), and CLK1, CLK2 and CLK4 help regulate the aurora B-
dependent abscission checkpoint during mitosis (Petsalaki and Zachos, 2016). CLK kinases 
phosphorylate the so-called ‘SR protein’ splice factors, facilitating their activation and release 
from nuclear speckles (Naro and Sette, 2013). However CLK kinases can also phosphorylate 
non-SR protein splice factors including the spliceosome-associated SPF45 (Liu et al., 2013).  
CLK activity is increasingly associated with the development and progression of cancer (Naro 
and Sette, 2013; Corkery et al., 2015; Czubaty and Piekielko-Witknowska, 2017). As a result 
there is considerable interest in developing selective CLK  inhibitors that block tumour growth 
(Schmitt et al., 2014; ElHady et al., 2017; Murar et al., 2017; Sun et al., 2017; Riggs et al., 2017; 
Walter et al., 2017). CLK1 is also a potential target in the treatment of Alzheimer’s (Jain et al., 
2014) and has been earmarked for the treatment of Duchenne’s muscular dystrophy as its 
inhibition causes the skipping of a mutated exon (Ogawa and Hagiwara, 2012; Sako et al., 
2017). CLK targeting has also been proposed for the treatment of viral infection including HIV-
1 (Wong et al., 2011) and influenza (Karlas et al., 2010; Zu et al., 2015). 
The human CLK1 gene is comprised of 13 exons, and is alternatively spliced expressing either 
a full length or truncated protein that lacks the catalytic domain (Duncan et al., 1997; 
Menegay et al., 2000). There are at least two alternative splicing mechanisms that result in 
the expression of truncated CLK1: skipping of exon 4 (Duncan et al., 1997) and intron 
retention, the latter reported in the mouse Clk1 gene (Ninomiya et al., 2011). Most tissues 
express both full length and truncated CLK1, but their balance is altered following exposure 
to environmental stresses such as heat or osmotic shock (Menegay et al., 2000; Ninomiya et 
al., 2011; Corkery et al., 2015). There is a need to understand how CLK1 expression, including 
its alternative splicing, changes and is regulated in normal development and disease. We 
examined the alternative splicing of human CLK1 in a range of cancer cell lines, in response to 
environmental stress, and in response to CLK1 inhibition with TG003.  
 
2. Materials and methods 
 
2.1 Cell lines, cell culture and treatments 
Prostate cancer cell lines (androgen independent PC3 and DU145, androgen dependent VCaP, 
and normal prostate epithelium PNT2) were cultured in Dulbecco’s Modified Eagle’s Medium 
(DMEM) containing 5mM glucose and L- glutamine, 10% fetal bovine serum (FBS), 100 U/ml 
streptomycin and 100μg/ml penicillin and 1% sodium pyruvate. Leukemic cell lines CMK 
(acute megakaryocytic leukemia); MOLT4 (acute lymphoblastic leukemia); RPKV8226 
(myeloma); K562 (chronic myelogenous leukemia); HL60 (promyelocytic leukemia); and TK6 
(hereditary spherocytosis) were cultured in RPMI medium with the same additives. All cell 
culture reagents were obtained from Sigma-Aldrich.  
The alkaloid harmine and the CLK1 inhibitor benzothiazole TG003 were obtained from Sigma-
Aldrich. TG003 stock solution was prepared in dimethylsulfoxide (DMSO) and harmine was 
dissolved in 50% ethanol. 1x106 DU145 PCa cells were treated with varying concentrations 
(10nM -100µM) of TG003 and 1-5M harmine for 48 hours. For heat shock treatments, DU145 
cells were incubated for one, three or six hours at 42oC in a tissue culture incubator (Orbital, 
S150 Stuart). Osmotic stress was induced by treatment with 200mM or 400mM sorbitol 
(Sigma-Aldrich) for three hours. 
 
2.2 RNA extraction and cDNA synthesis 
RNA extraction was performed using the RNA miniprep kit from Agilent Technology Ltd, USA 
as per manufacturer’s instructions. RNA quality was verified on 1% (w/v) agarose gels and the 
concentration and purity was determined using Nanodrop (Spectrophotometric). cDNA 
synthesis was performed using reverse transcriptase and a mixture of oligo (dT) and random 
primers as per manufacturer’s instructions (Promega). 1g RNA was mixed with 0.5µl of the 
oligo and 0.5µl random primers provided by the kit in a volume of 5.0µl with nuclease free 
water. The samples were placed in a heat block at 70oC for five minutes, then chilled on ice 
for five minutes. To each 5µl RNA sample, 15µl of reverse transcription reaction mix was 
added. Primers were allowed to anneal at 250C for 5 min, cDNA synthesis proceeded at 42oC 
for one hour and finally the reverse transcriptase was inactivated at 70oC for 15 min.   
 
2.3 Polymerase chain reaction 
cDNA was amplified with the GoTaq kit (Promega) as per manufacturer’s instructions using 
the CLK1 primers (E3F1 CAAGGATGTGAACCTGGACATCGC and E4F1 
GGAGGTCACCTGATCTGTCAG forward primers in exons 3 and 4 respectively, and reverse 
primers E5R1 CTCCTTCACCTAAAGTATCAAC and E5R2 CTGCTACATGTCTACCTCCCGC in exon 5, 
as well as -actin forward TTAAGGAGAAGCTGT  and reverse GTTGAAGGTAGTTTCGTGGAT  to 
verify cDNA synthesis; all sequences shown are 5′-3′). PCR cycles were as follows: 95oC for 2 
minutes (initial denaturation), then 95oC for 1 min. (denaturation), 59oC for 1 min. 
(annealing), 72oC for 1.5 min. (extension); cycles were repeated 34 times followed by a final 
extension step at 72oC for 5 min. 
 
2.4 Agarose gel electrophoresis 
20l aliquots of amplified PCR products were run in 2% (w/v) agarose gel at 95V and 400AMP 
for 1 hour. Agarose gels were stained in 0.2mg/ml ethidium bromide (Sigma-Aldrich). Gel 
images were obtained using UV transluminator (Fisher Scientific). 
2.5 Statistical analysis 
All statistical tests were performed using GraphPad Prism 7.03. Mann-Whitney t-tests were 
used to compare significance between two groups. For multiple comparisons, one-way 
ANOVAs with Kruskal-Wallis test were performed. For all graphs, n.s. denotes not significant, 
* = p ≤ 0.05, ** = p ≤ 0.01, *** = p ≤ 0.001. 
 
3. Results 
3.1 Features of CLK1’s exon 4 and intron 4 
We began by examining the exon/intron structure of the human CLK1 gene, focusing on exon 
4 and surrounding intronic sequence (Fig. 1). The structure of the human CLK1 gene mirrors 
closely that of the corresponding mouse gene, with a short intron separating exons 4 and 5 in 
both species and very high sequence conservation in exon 4 and flanking intron. Skipping of 
exon 4 has previously been reported in the human CLK1 gene (Duncan et al., 1997), and both 
exon 4 skipping and intron 4 retention has been reported in the mouse gene (Ninomiya et al., 
2011). Exon 4 skipping results in a premature stop codon interrupting the amino-terminal 
regulatory domain, resulting in a truncated 120 amino-acid previously named CLK1T (Duncan 
et al., 1997). Intron 4 retention also creates a premature stop codon and a truncated CLK1, 
albeit a little longer (160 amino-acids). We propose to call the former CLKT1 (arising from exon 
4 skipping) and the latter CLK1T2 (due to intron 4 retention, Fig. 1A and 1B). 
 We analysed the exon 4 sequence on the RBPmap and SROOGLE servers (Paz et al., 2014; 
Schwart et al., 2009) and noted a number of interesting features (Fig. 1C). Firstly, there is a 
weak pyrimidine tract with three purines preceding exon 4 (…CUUGACGUUUCCAG, consensus 
Y11NCAG, where Y is U or C). The 5′ splice site at the end of exon 4 is also not especially strong, 
GATguauag compared to the consensus MAGguragu where M is A or C and R is A or G. This 
suggests that the baseline efficiency of exon 4 recognition and splicing is likely to be low. In 
contrast the end intron 4 possesses a better pyrimidine tract (…UUCUCUCUUUUAG). This 
suggests that more efficient exon 4 inclusion may require the action of specific splice factors 
acting through exonic splice enhancers (ESEs). Using the SROOGLE server (sroogle.tau.ac.il) 
we identified the presence of putative ESEs particularly at the beginning of exon 4 (Zhang and 
Chasin, 2004); these correspond to potential binding sites for splice factors SRSF1 and SRSF2, 
(Schwartz et al, 2008). Additional potential splice factor binding sites were identified using 
RBPmap (Paz et al., 2014), ESE finder (Cartegni et al., 2003) and SpliceAid (Piva et al., 2009). 
Exon 4 appears particularly dense with potential SRSF1 binding sites (Fig. 1C). Through 
SROOGLE we also noted the presence of a potential intronic splice silencer (ISS) immediately 
following the 5′ splice site at the end of exon 4.  
 
3.2 Alternative splicing of CLK1 in of cancer cell lines 
Based on the reported skipping of exon 4 and retention of intron 4 in mouse embryo 
fibroblast-like NIH-3T3 cells (Ninomiya et al., 2011) we designed human-specific primers for 
RT-PCR  including a forward primer in exon 3 and in exon 4 and two reverse primers in exon 
5 that could be used to detect these alternative splicing events (Fig. 1A). Skipping of exon 4 
had previously also been reported in the human embryonic kidney cell line 293T (Duncan et 
al., 1997). We surveyed a range of human cell lines to look for evidence of CLK1 alternative 
splicing. We observed variable exon 4 skipping in all cell lines examined, and intron 4 retention 
in all but one cell line (Fig. 2). More specifically, alternative splicing of CLK1 was observed in 
PC3 and DU145 androgen-independent prostate cancer cell lines, and in androgen-dependent 
VCaP cells. CLK1 alternative splicing was also apparent in the normal prostate epithelium cell 
line PNT2, albeit with a higher degree of intron retention. We also observed alternative 
splicing of CLK1 in the cervical cancer cell line HeLa and in fetal kidney HEK293 cells (Fig. 2A). 
We also examined CLK1 alternative splicing in a range of leukemic cell lines (Fig. 2B). In the 
leukemic cell lines we observed widespread exon 4 skipping and intron 4 retention; however 
intron 4 retention was less prominent and was not detectable in MOLT4 acute lymphoblastic 
leukemia cells. In summary there is clear evidence that CLK1 is alternatively spliced in all 
cancer cell lines examined, but the degree of exon 4 skipping or intron 4 retention varies 
significantly. 
 
3.3 Effect of heat shock, osmotic shock and harmine on CLK1 alternative splicing 
Heat shock and osmotic stress (the latter through exposure to high concentrations of sorbitol) 
were previously shown to promote the maturation of murine Clk1 mRNA (Ninomiya et al. 
2011). We sought to determine whether or not the human CLK1 transcript is similarly 
affected. DU145 prostate cancer cells were grown at 42°C for one, three and six hours. After 
only one hour exon 4 skipping and intron 4 retention could not be detected (Fig. 3A). We 
confirmed that increased exon 4 inclusion and decreased intron 4 retention corresponded, as 
expected, to increased CLK1 protein levels (Fig. 3B). We exposed DU145 cells to osmotic stress 
in 200 and 400mM sorbitol. In these conditions we also observed a reduction in exon 4 
skipping and loss of intron 4 retention (Fig. 3C). We also treated DU145 cells with the drug 
harmine, a multifunctional alkaloid derived from the plant Peganum harmala that has a range 
of effects including antimicrobial, antitumour, and hallucinogenic (Patel et al., 2010; 
Moloudizargari et al., 2013). Harmine is also a potent inhibitor of the splice factor DYRK1A 
(Göckler at al., 2009), and it causes changes in alternative splicing in vivo (Herrendorf et al., 
2016). DU145 cells were treated with 1-5M harmine for six hours. At the lowest 
concentration (1M) harmine entirely eliminated both exon 4 skipping and intron 4 retention. 
Thus we confirm that, like mouse Clk1, the human CLK1 gene responds to heat shock and 
osmotic stress by promoting productive CLK1 splicing (mRNA that encodes full length CLK1), 
and the same effect is observed following exposure to the alkaloid harmine. 
 
3.4 Effect of TG003-mediated CLK1 inhibition on alternative splicing 
The benzothiazole compound TG003 was developed as a specific inhibitor of CLK1 (Muraki et 
al., 2004). TG003 has previously been shown to promote productive CLK1 splicing in murine 
cells; we therefore sought to confirm this apparent autoregulatory effect in human cells. 
DU145 prostate cancer cells were treated with a wide range of TG003 concentrations, 10nM 
to 100M. A clear shift in alternative splicing could be observed at 100nM (Fig. 4A). At the 
highest concentrations of TG003 no detectable exon 4 skipping or intron 4 retention was 
observed. We also examined CLK1 protein levels and observed that at the higher TG003 
concentrations CLK1 protein levels clearly increased, consistent with the occurrence of more 
productive CLK1 splicing (Fig. 4B).  
The inhibition of CLK1 with TG003 has been shown to result in significant changes in global 
exon skipping rates (Sakuma et al., 2015). We examined the effect of TG003 on the alternative 
splicing of four apoptosis-related genes, Bcl-X (Boise et al., 1993), Mcl-1 (Bae et al., 2000), 
survivin (Mahotka et al., 1999) and CASP9 (Srinivasula et al., 1999) as well as the cancer-
associated gene FGFR10P (FGFR10 oncogene partner; Lee et al., 2013). In all cases we 
observed clear changes in their alternative splicing, suggesting that the inhibition of CLK1 has 
a significant and widespread impact on alternative splicing of cancer-associated genes.  
 
4. Discussion 
The splice factor kinase CLK1, a member of the CDC2-like CLK family, contributes to the 
regulation of alternative splicing by phosphorylating SR proteins and other splice factors 
including the spliceosome-associated SPF45 (Liu et al., 2013). The CLK1 gene is alternatively 
spliced (Duncan et al., 1997; Ninomiya et al., 2011), producing both catalytically active and 
truncated, inactive CLK1, the latter as a result of exon 4 skipping (120 amino-acids long CLK1T1) 
or intron 4 retention (160 amino-acids long CLK1T2). CLK1 is increasingly linked to the 
pathobiology of several diseases, including neurological conditions, metabolic disorders and 
cancer. We examined the baseline alternative splicing of CLK1 in a range of human cancer cell 
lines, focusing on the skipping of exon 4 and retention of intron 4. We found evidence of 
widespread, and highly variable CLK1 alternative splicing in 12 cell lines. Whereas significant 
rates of exon 4 skipping could be detected in leukemic cell lines, intron 4 retention was less 
prominent than in the prostate cancer cell lines. Both types of CLK1 alternative splicing lead 
to the expression of truncated CLK1T1 (exon 4 skipping) and CLK1T2 (intron 4 retention), each 
lacking the catalytic domain. The presence of high levels of these CLK1 splice isoforms 
suggests that they are not entirely removed by nonsense-mediated decay (NMD). The ability 
of retained introns described as ‘detained’ introns to evade NMD has previously been 
reported (Boutz et al., 2015). Detained introns are a special class of introns that are poorly 
spliced and retained in the nucleus in order to modulate gene expression (Fu, 2017; Wegener 
and Müller-McNicoll, 2017). Interestingly, CLK1 itself has been shown to regulate the 
alternative splicing of nuclear ‘detained’ introns in hundreds of other genes (Boutz, Bhutkar 
& Sharp, 2015). We suggest that the co-expression of truncated, catalytically inactive CLK1 is 
functionally required to maintain an appropriate level of CLK1 activity. Interestingly, our 
results show that CLK1 inhibition with TG003 alters the balance of pro- and anti-apoptotic 
splice isoforms of CASP9, MCL-1, BCL-X and survivin genes, suggesting that the baseline 
activity of CLK1 needs to be precisely maintained by cancer cells in order to prevent apoptosis. 
Future work will determine whether or not the effect of TG003 on the alternative splicing of 
these genes is directly attributable to CLK1 inhibition or due to an indirect effect. 
We confirm that the alternative splicing of CLK1 changes radically in response to severe 
environmental shock. We observe that heat shock, osmotic shock and harmine treatment all 
very rapidly lead to more efficient CLK1 splicing, producing higher levels of catalytically active 
CLK1. Heat shock has been shown to lead to rapid dephosphorylation of the SR protein SRp38 
(SRSF10) by protein phosphatase 1 (Shi and Manley, 2007). We note the presence of a 
putative SRSF10 binding site in exon 4 (Fig. 1C). We suggest that the equally rapid shift to 
productive CLK1 splicing in heat shock helps to augment the phosphorylation of SR proteins. 
The impact of harmine on the intron retention and exon skipping of CLK1 pre-mRNA had not 
been previously assessed (Ogawa & Hagiwara, 2012).  We show that exposure of DU145 cells 
to 1M harmine for six hours also promoted the maturation of CLK1 pre-mRNA. Interestingly, 
CLK1 expression is also induced in hypoxic cells (Eisenreich et al., 2013; Jakubauskiene et al., 
2015; Bowler et al., 2018). Activation of the CLK1 promoter occurs through hypoxia inducible 
factor (HIF-1); however the effect of hypoxia on CLK1 alternative splicing has not been 
examined. Taken together these findings indicate that cells need higher levels of catalytically 
active CLK1 to survive in conditions of extreme cellular stress. 
We observed that inhibition of CLK1 with the benzothiazole TG003 also promoted productive 
CLK1 splicing and at higher concentrations increased levels of CLK1 protein. There are several 
precedents of splice factors that autoregulate their expression through alternative splicing; 
these include Muscleblind-like 1 (MBNL1) (Gates et al., 2011), the FOX splice factors 
(Damianov and Black, 2010), and the SR proteins (Lareau and Brenner, 2015) including SRSF1 
(Sun et al., 2010). Analysis of exon 4 and flanking intronic sequence suggests that exon 4 is 
not flanked by strong splice sites, and that several SR proteins, including SRSF1, SRSF2 and 
SRSF10, may bind and contribute to the regulation of exon 4 inclusion. SRSF1 was the first 
splice factor to be described as a proto-oncogene (Karni et al., 2007). SRSF1 is multifunctional, 
working at multiple levels of gene expression both in the nucleus and cytoplasm (Das and 
Krainer, 2014). In regulating alternative splicing, SRSF1 can both promote (Lopez-Mejia et al., 
2013) and repress (Jumaa and Nielsen, 2000) the inclusion of cassette exons. SRSF1 is also a 
well characterized substrate of CLK1. CLK1’s N-terminal domain contacts SRSF1; this 
interaction is required for hyperphosphorylation of SRSF1 by CLK1 and facilitates SRSF1 
binding to RNA targets (Aubol et al., 2014). It is tempting to speculate that SRSF1 is involved 
in the autoregulation of CLK1 alternative splicing. There is also a potential TIA-1 binding site 
around the 3′ splice site; TIA-1 is involved in 3′ splice site recognition (Huang et al., 2017). 
HnRNP H (Masuda et al., 2008) is often associated with splice silencers; there are also 
potential binding sites for this hnRNP protein in exon 4. Future research will determine 
precisely which splice factors are involved in CLK1 autoregulation through alternative splicing. 
We suggest that CLK1 activity in both transformed and normal cells is carefully regulated via 
CLK1 alternative splicing through both exon 4 skipping and intron 4 retention. We suggest 
that CLK1 autoregulates its expression by favouring the expression of truncated isoforms, 
CLK1T1 and CLKT2 (Figure 5). Extreme environmental stress or CLK1 inhibition shifts the balance 
clearly towards productive splicing, increasing levels of full length CLK1. The function and 
regulation of expression of truncated splice isoforms CLK1T1 and CLKT2 remains to be fully 
determined. Novel therapies that target CLK1 will need to take into account the presence of 
truncated CLK1 isofoms and the autoregulatory loop. 
 Figure Legends 
 
Fig. 1. Analysis of CLK1’s alternatively spliced exon 4 and intron 4. (A) Schematic of CLK1 splice 
isoforms (exon 4 skipped and intron 4 retained). The position of the primers used for PCR is 
indicated. (B) Structure of CLK1 protein and its splice isoforms. CLK1 comprises an N-terminal 
domain which is retained in both splice isoforms. The full length protein includes a CDC-like 
protein kinase domain with an ATP binding cassette. (C) Analysis of human CLK1 exon 4 and 
flanking intronic sequence. Putative splice factor binding sites are indicated. Data was 
obtained using RBPmap (rbpmap.technion.ac.il) and visualised on the UCSC genome browser. 
Exon 4 and surrounding intronic sequences are shown below; three putative exonic splice 
enhancers (green) and an intronic splice silencer (red) were identified via SROOGLE (Schwartz 
et al., 2008).  
 
Fig. 2. Alternative splicing of CLK1 in a range of cancer cell lines. Primers E3F1 and E5R2 were 
used to determine the extent of exon 4 skipping (E4S); primers E4F1 and E5R1 were used to 
measure intron 4 retention (I4R). The position of each splice isoform is indicated. (A) 
Expression in prostate cancer cell lines PC3, DU145 and VCaP, and for comparison normal 
prostate epithelium PNT2, HeLa (cervical cancer) and HEK293 (human embryonic kidney). (B) 
CLK1 alternative splicing in leukemic cell lines: CMK (acute megakaryocytic leukemia); MOLT4 
(acute lymphoblastic leukemia; RPKV8226 (myeloma); K562 (chronic myelogenous leukemia); 
HL60 (promyelocytic leukemia); and TK6 (hereditary spherocytosis). PSI values (rates of exon 
or intron inclusion) are shown on the right based on N=3 repeats. 
 
Fig. 3. Effect of heat shock, osmotic shock and harmine treatment on CLK1 alternative splicing. 
(A) DU145 prostate cancer cells were exposed to extreme heat shock (42°C) for 1, 3 and 6 hrs. 
PSI values (rates of exon or intron inclusion) are shown on the right based on N=3 repeats. (B) 
CLK1 upregulation in heat shock confirmed at a protein level, quantified relative to GAPDH, 
N=3. (C) DU145 cells were exposed to 200mM and 400mM sorbitol for 3 hrs, or treated with 
1-5 M of the alkaloid harmine for 6 hrs.  
 
Fig. 4. Effect of CLK1 inhibition with the benzothiazole TG003 on CLK1 alternative splicing. 
DU145 cells were treated for 48hrs with increasing doses of TG003. DMSO: dimethylsulfoxide 
solvent alone. (A) Effect on the expression of the splice isoforms at RNA level and (B) at a total 
protein level (-actin loading control). PSI values (rates of exon or intron inclusion) are shown 
on the right based on N=3 repeats; upregulation of CLK1 protein was confirmed relative to -
actin (N=3). Statistical comparisons are shown. (C) Effect of TG003 treatment on the 
alternative splicing of four apoptotic genes BcL-X, Mcl-1, survivin and caspase 9, and on 
FGFR10P (FGRF1 oncogene partner). 
 
Fig. 5.  Proposed model summarising the proposed autoregulation of CLK1. In normal 
physiological conditions, CLK1 suppresses its own efficient splicing through skipping of exon 
4 and retention of intron 4. In conditions of environmental stress, or if CLK1 activity is 
inhibited, CLK1 pre-mRNA is spliced more efficiently (productive splicing), increasing levels of 
CLK1 protein. 
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